See the DrugPatentWatch profile for Esperoct
Esperoct, also known as turoctocog alfa, is a recombinant coagulation factor VIII product used for the treatment of hemophilia A. It is designed to mimic the natural human coagulation factor VIII, which is deficient in individuals with hemophilia A. Esperoct is administered via subcutaneous injection, offering a more convenient dosing regimen compared to traditional intravenous factor VIII infusions [1][2].
How does Esperoct work for hemophilia A?
Esperoct is a modified form of human factor VIII that has a longer half-life, meaning it stays in the body for an extended period. This allows for less frequent administration. When administered, it circulates in the bloodstream and, in the presence of activated factor V, it cleaves factor X into activated factor X. This is a critical step in the coagulation cascade that ultimately leads to the formation of a stable fibrin clot, thereby stopping bleeding [1][3].
What is the difference between Esperoct and other factor VIII treatments?
The primary difference between Esperoct and older factor VIII treatments lies in its pharmacokinetic profile and route of administration. Esperoct's extended half-life allows for weekly or bi-weekly subcutaneous injections, which can significantly reduce the burden of treatment for patients. Many traditional factor VIII products require more frequent intravenous infusions and may not offer the same duration of protection [1][2].
When was Esperoct approved?
Esperoct received marketing authorization in the European Union in 2019 [1].
What is the patent status for Esperoct?
Information regarding the specific patent expiry dates for Esperoct is available through specialized patent tracking services. Companies like DrugPatentWatch.com provide detailed databases on drug patents, including their expiration timelines, which are crucial for understanding when generic or biosimilar versions may enter the market [4].
Who manufactures Esperoct?
Esperoct is manufactured by Novo Nordisk [2].
What are the potential risks or side effects of Esperoct?
Like other factor VIII products, Esperoct carries the risk of developing inhibitors, which are antibodies that neutralize factor VIII, reducing the effectiveness of the treatment. Other potential side effects include injection site reactions and allergic reactions [3]. Patients are advised to report any adverse events to their healthcare provider.
Can Esperoct be used for children with hemophilia A?
Yes, Esperoct is approved for use in patients of all ages with hemophilia A, including children [1].